Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.13
Change (%) Stock is Up 0.13 (1.86%)
Volume8,058
Data as of 06/27/17 11:14 a.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
06/14/17Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
06/12/17Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego
06/06/17Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
05/30/17Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
Upcoming EventsMore >>
DateTitle
08/15/17
through
08/16/17
Eiger BioPharmaceuticals at the Wedbush PacGrow Healthcare Conference
LocationNew York, NY
09/10/17
through
09/12/17
Eiger BioPharmaceuticals at the Rodman & Renshaw 19th Annual Global Investment Conference
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.